Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Our scientific activity belongs to tumor immunology: in the last fifteen years, we have contributed to the molecular definition of tumor antigens recognized by cytolytic T lymphocytes, both in human and mice, and to the validation of cancer immunotherapy in appropriate preclinical models. Here we describe two findings that we recently made in this field. The first is the discovery of a new mechanism of production of antigenic peptides, based on the splicing of peptides by the proteasome. The second is the discovery of an important mechanism of tumor resistance to immune rejection. The major interest of this mechanism is that it can be fought with pharmacological agents, which could be used to boost the efficacy of immunotherapy in cancer patients.

Type

Journal article

Journal

Bulletin et memoires de l'Academie royale de medecine de Belgique

Publication Date

01/2007

Volume

162

Pages

352 - 356

Addresses

Institut Ludwig pour la Recherche sur le Cancer, Branche de Bruxelles.

Keywords

T-Lymphocytes, Animals, Humans, Mice, Neoplasms, Disease Models, Animal, Proteasome Endopeptidase Complex, Peptides, Cancer Vaccines, Antigens, Neoplasm, Histocompatibility Antigens, Immunotherapy, Protein Splicing, Clinical Trials as Topic